Cantaloupe (CTLP) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
6 Feb, 2026Executive summary
Revenue for the quarter ended December 31, 2025, increased 6.8% year-over-year to $78.7 million, driven by higher transaction and subscription fees and a modest rise in equipment sales.
Net loss for the quarter was $0.07 million, compared to net income of $5.0 million in the prior year quarter, primarily due to higher merger, acquisition, and integration expenses.
The company is in the process of being acquired by 365 Retail Markets, with the transaction expected to close in the first half of 2026, pending regulatory approval.
Financial highlights
Subscription and transaction fees rose 7.1% year-over-year to $69.7 million for the quarter; equipment sales increased 4.6% to $9.0 million.
Gross margin declined to 34.8% from 38.6% year-over-year, mainly due to increased transaction fee costs.
Adjusted EBITDA for the quarter was $10.8 million, down from $19.6 million in the prior year quarter.
Cash and cash equivalents stood at $53.0 million as of December 31, 2025.
Outlook and guidance
Management expects the merger with 365 Retail Markets to close in the first half of 2026, subject to regulatory clearance.
The company believes its current financial resources are sufficient to fund operations for the next twelve months.
Latest events from Cantaloupe
- Revenue up 4.3% to $78.7M; merger with 365 Retail Markets expected to close May 2026.CTLP
Q3 2026 - Shareholders to vote on $11.20/share cash merger, board recommends approval.CTLP
Proxy Filing - Shareholders to vote on $11.20/share cash merger with 365 Retail Markets, board recommends approval.CTLP
Proxy Filing - Shareholders to receive $11.20 per share in cash as part of a unanimously approved merger.CTLP
Proxy Filing - Shareholders approved the merger and compensation proposals, with final results pending SEC filing.CTLP
AGM 2025 - Revenue up 13% to $70.8M, net income more than doubled, FY25 outlook reaffirmed.CTLP
Q1 2025 - FY24 revenue up 10.2% to $268.6M, EBITDA nearly doubled; strong FY25 growth outlook.CTLP
Q4 2024 - Q3 FY2025 revenue and net income surged, driven by margin gains and a major tax benefit.CTLP
Q3 2025 - Q2 FY25 revenue up 12.8%–13% to $73.7M, with margin and earnings growth momentum.CTLP
Q2 2025